1. Home
  2. PMI vs MDXH Comparison

PMI vs MDXH Comparison

Compare PMI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMI

Picard Medical Inc.

N/A

Current Price

$2.46

Market Cap

202.7M

Sector

N/A

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.33

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMI
MDXH
Founded
1981
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
202.7M
167.8M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
PMI
MDXH
Price
$2.46
$3.33
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
2.5M
182.7K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,767,000.00
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
8.81
21.68
52 Week Low
$1.90
$1.35
52 Week High
$13.68
$5.33

Technical Indicators

Market Signals
Indicator
PMI
MDXH
Relative Strength Index (RSI) N/A 34.01
Support Level N/A $3.31
Resistance Level N/A $3.74
Average True Range (ATR) 0.00 0.17
MACD 0.00 0.00
Stochastic Oscillator 0.00 7.27

Price Performance

Historical Comparison
PMI
MDXH

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: